Abstracts tagged "Chemokines and systemic lupus erythematosus (SLE)"

Abstract Number: 783 • 2018 ACR/ARHP Annual Meeting
Procalcitonin and CXCL9 As Potential Biomarkers for Pneumonia in Patients with Systemic Lupus Erythematosus
Hilda Fragoso-Loyo¹, Andrea Hinojosa-Azaola¹, Ricardo Ríos-Corzo², John Hernandez-Flores³, Mariana Lopez-Lopez¹, Ariadna Díaz-Mora¹, Alma Lilia Pulido-Ramírez², Jose Sifuentes-Osornio³, María de Lourdes Guerrero-Almeida⁴, Luis Alfredo Ponce de León-Garduño⁴, Eduardo Carrillo-Maravilla⁵, Luis Llorente¹ and Yemil Atisha-Fregoso^6,7, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²Medicine Division, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ³Internal Medicine, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁴Infectious Diseases Department, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁵Medicina Interna, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico, ⁶Instituto Tecnológico de Estudios Superiores de Monterrey, Mexico City, Mexico, ⁷Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Background/Purpose: Pneumonia is an important cause of death in patients with SLE. In general population, recommendations encourage the use of procalcitonin for management of pneumonia,…
Abstract Number: 1868 • 2013 ACR/ARHP Annual Meeting
Chemokine Expression In Systemic Lupus Erythematosus
Eoghan M. McCarthy¹, Joan Ní Gabhann², Siobhán Smith², Ruth Lee³, Gaye Cunnane⁴, Michele Doran⁵, Donough G. Howard³, Paul G. O'Connell¹, Grainne M. Kearns⁶ and Caroline Jefferies², ¹Rheumatology, Beaumont Hospital, Dublin, Ireland, ²Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland, ³Rheumatology, Beaumont Hospital, Dublin 9, Ireland, ⁴Dept of Rheumatology, St James's Hospital, Dublin, Ireland, ⁵Rheumatology Dept, St James's Hospital, Dublin, Ireland, ⁶Rheumatology Department, Beaumont Hospital, Dublin, Ireland
Background/Purpose: Systemic lupus erythematosus(SLE) is a systemic autoimmune disease characterised by the deregulated activation of T and B lymphocytes, production of autoantibodies and the formation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].